Wells Fargo
EDIT icon

Wells Fargo’s Editas Medicine EDIT Stock Holding History

Wells Fargo’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10,000
Closed -$411K – 7330
2021
Q3 		$411K Buy
+10,000
New +$548K ﹤0.01% 4770

Other funds holding EDIT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wells Fargo's EDIT Position: Q1 2026 in Review

Wells Fargo reduced its Editas Medicine (EDIT) stake by 37% in Q1 2026, selling an estimated $128K and leaving 102,030 shares worth $252K. The position accounts for ﹤0.01% of the portfolio, ranked #4571.

Wells Fargo first reported a position in EDIT in Q1 2016 and has held it in 41 quarters since. The position peaked at $11.2M in Q2 2021. 208 funds tracked by Wall St. Rank hold EDIT as of Q1 2026.

  • Wells Fargo held 102,030 shares of Editas Medicine worth $252K as of Q1 2026.
  • Wells Fargo sold 60,714 Editas Medicine shares in Q1 2026, an estimated $128K.
  • Editas Medicine made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #4571 holding.
  • Wells Fargo first reported a position in Editas Medicine in Q1 2016 and has held it in 41 quarters since.
  • Wells Fargo's Editas Medicine position peaked at $11.2M in Q2 2021.
  • 208 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.